LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Innovation Pipeline | Explore LivaNova's product development strategy, focusing on the Essenz heart-lung machine and potential breakthroughs in sleep apnea and depression treatments |
Market Dynamics | Delve into LivaNova's positioning in the cardiopulmonary and neuromodulation segments, examining competitive pressures and expansion opportunities |
Financial Outlook | Analysts project 6-7% organic growth for LivaNova, with potential to exceed this range. Average price target from analysts stands at $56.50 |
Regulatory Landscape | Uncover the impact of regulatory decisions on LivaNova's growth prospects, including FDA submissions and Medicare coverage reconsiderations |
Metrics to compare | LIVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLIVNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −14.3x | 29.9x | −0.7x | |
PEG Ratio | 0.01 | 0.03 | 0.00 | |
Price/Book | 2.7x | 2.9x | 2.6x | |
Price / LTM Sales | 2.3x | 4.0x | 3.4x | |
Upside (Analyst Target) | 14.2% | 62.2% | 37.6% | |
Fair Value Upside | Unlock | 16.8% | 4.6% | Unlock |